Chapter 40: Anxiety Disorders – Medication & Management

Chapter 40 details the complex nature of anxiety disorders, a group of clinically distinct psychiatric illnesses characterized by excessive fear, worry, anxiety, and related behavioral and somatic manifestations. These conditions, including Generalized Anxiety Disorder (GAD), Panic Disorder (PD), and Social Anxiety Disorder (SAD), are highly prevalent, chronic, and often co-occur with major depression. Pathologic anxiety stems from abnormal fear processing and emotional hyperarousal, involving the dysregulation of key neurotransmitters such as serotonin (5-HT), norepinephrine (NE), and gamma-aminobutyric acid (GABA) within various brain circuits. Before diagnosis, it is essential to rule out medical conditions or exogenous chemical causes. The long-term objective of treatment is complete remission and restoration of the patient’s prior functional status. Successful management integrates both nonpharmacologic approaches, such as Cognitive-Behavioral Therapy (CBT)—highly effective for GAD—and pharmacologic interventions. First-line drug treatments for chronic anxiety disorders typically include Selective Serotonin Reuptake Inhibitors (SSRIs) and Serotonin–Norepinephrine Reuptake Inhibitors (SNRIs), which require four to eight weeks to achieve a therapeutic effect. Benzodiazepines (BZDs), which enhance GABA-A receptor response, are utilized for the rapid, short-term management of acute symptoms or exacerbations, but their long-term use is discouraged due to the risks of tolerance and dependence. Second-line options for GAD include azapirones like buspirone, which has a delayed onset and minimal abuse potential, or the Tricyclic Antidepressant (TCA) imipramine. Specialized populations, such as the elderly, require tailored therapy (e.g., BZDs with shorter half-lives like lorazepam), and drug choices during pregnancy must weigh maternal risks against potential fetal complications. Patient compliance requires comprehensive education on the chronic nature of the illness, expected treatment duration (often 12 months after remission for GAD), and monitoring for adverse effects like sexual dysfunction, which is common with SSRIs.